Agilent Technologies appoints Adam Elinoff as new CFO

SANTA CLARA - Agilent Technologies Inc. (NYSE:A), a $41.6 billion market cap company trading near its 52-week high of $153.84, announced Monday the appointment of Adam S. Elinoff as chief financial officer, effective November 17.

Elinoff joins the analytical and clinical laboratory technologies company after 19 years at Amgen, where he most recently served as vice president of finance and treasurer. During his tenure at the biotechnology company, he held various leadership positions including regional CFO for Europe, the Middle East, Africa, Latin America, and Canada, where he managed a $6 billion P&L.

"We are thrilled to welcome Adam to the Agilent team and look forward to partnering with him as we build on our momentum and execute our financial priorities," said Padraig McDonnell, Agilent president and CEO, in a press release statement.

McDonnell added that Rodney Gonsalves, who has been serving as interim chief financial officer, will continue in his role as corporate controller and principal accounting officer.

Prior to his career at Amgen, Elinoff worked in finance leadership positions at Shire Pharmaceuticals and International Rectifier. He began his career as a Peace Corps volunteer in Senegal. Elinoff holds a Bachelor of Arts in Economics from Hamilton College and an MBA from Arizona State University’s W.P. Carey School of Business.

Agilent Technologies, which provides instruments, software, services, and expertise for analytical and clinical laboratory applications, generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. InvestingPro analysis shows the company maintains strong financial health with a 52.6% gross profit margin and has consistently paid dividends for 14 consecutive years. For detailed insights and 15 additional ProTips about Agilent’s financial outlook, investors can access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Agilent Technologies has received a series of positive assessments from various investment firms. Rothschild Redburn initiated coverage on Agilent with a Buy rating and set a price target of $165, emphasizing the company’s diversified business structure. UBS upgraded Agilent from Neutral to Buy, raising its price target to $170, citing the company’s potential for growth leadership and its recent launches in liquid chromatography instruments, which account for about 15% of its sales. TD Cowen also maintained its Buy rating on Agilent, with a price target of $150, following strong fiscal third-quarter performance and a promising outlook for its pharmaceutical and Chemical & Applied segments.

Additionally, Agilent has introduced a new line of high-performance liquid chromatography columns aimed at biotherapeutics applications, featuring proprietary technology for improved performance. The company also announced a quarterly dividend of 24.8 cents per share, payable on October 22, 2025, to shareholders of record as of September 30, 2025. These developments reflect Agilent’s ongoing efforts to strengthen its market position and deliver value to its investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.